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ABSTRACT: Chromosome translocations that disrupt or alter gene function have been implicated in the 
pathogenesis of a variety of malignancies. Therefore, identification of a translocation breakpoint has be- 
come a mare  impor tant  means  by which to identify genes involved in cellular transformation. A common 
site of translocation in myeloid and lymphoid malignancies involves 11q23. One h u m a n  protooncogene, 
ETS1, has been localized to this chromosomal segment, and several tumors with 11q23 translocations have 
been shown to have altered ETS1 DNA migrat ion after restriction enzyme digestion. Two laboratories, 
however, have recent ly localized the 11q23 breakpoint region to a small  region of DNA telomeric of the 
CD3 loci, a region at considerable distance from the ETS1 gene locus. Therefore, it is difficult to reconcile 
the studies that suggest altered migration of fragments associated with ETS1 and lack of a localization 
of the breakpoint to a region near  the ETS1 gene. Recently, in our  studies to characterize the promoter/en- 
hancer region of the ETS1 protooncogene, we had the oppor tuni ty  to analyze DNA from 18 patients with 
acute leukemia involving chromosome 11q23 aberrations. We were unable to demonstrate rearrangement 
of the ETS1 gene in this group, thus confirming that the 11q23 breakpoint does not involve ETS1 protoon- 
cogene. In one patient, however, a DNA break in the region of the ETS1 promoter was detected repraduc- 
ibly. This DNA break was mapped to the major DNaseI hypersensitive site in the ETS1 promoter. Mapping 
from both sides of the break demonstrated that the break must have occurred during processing of the 
leukemic ceils for DNA analysis. Therefore, artifactual DNA breaks can occur at nuclease-hypersensitive 
sites of active genes. These data suggest that previous reports of chromosomal translocations involving 
the ETS1 protooncogene may  have resulted from DNA breaks at nuclease hypersensitive sites. This mech- 
anism may account for sporadic case reports of altered restriction enzyme fragment migration involving 
genes that are not ultimately shown to be associated with the chromosome translocation being examined. 
INTRODUCTION 
The h u m a n  protooncogene ETS1 was ident if ied by homol-  
ogy to the v-ets sequence of the E26 avian retrovirus [1]. In 
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chicken, the E26 retrovirus is responsible  for a mixed 
erythroid  and myeloid leukemia [2, 3]. The cel lular  homo- 
logue of v-ets is selectively expressed by quiescent  T and B 
lymphocytes  [4, 5]. We and other investigators have shown 
that ETS1 encodes a sequence-specific nuclear  t ranscript ion 
factor [6-8]. The high-level ETS1 expression observed in 
quiescent per ipheral  b lood T cells decreases to undetectable 
levels when  T-cell proliferation is induced by T-cell receptor- 
media ted  s t imulat ion [9]. S imilar  events occur  upon  B-cell 
activation [10]. These data have raised the poss ib i l i ty  that 
ETS1 may act to mainta in  l ympho id  cells in the quiescent  
state and thus is a potential  antioncogene.  
The human  ETS1 protooncogene has received consider-  
able attention because it is located on chromosome 11q23 [11], 
a breakpoint  commonly associated with  acute leukemia. The 
chromosomal  local izat ion of ETS1 has led several investiga- 
tors to speculate that mal ignant  t ransformation associated 
wi th  11q23 aberrations may be due to a d is rupt ion  or altera- 
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tion of the ETS1 gene [12-16]. Pulse field analysis of one tu- 
mor line demonstrated that the break of 11q23 mapped be- 
tween the CD3 and ETS1 genes [17]. In addition, in two 
studies, isolated cases of altered ETS1 migration after restric- 
tion enzyme digestion associated with 11q23 translocations 
was reported [12, 13]. Other studies, however, have failed to 
document breakpoints in the v-ets homologous domain of 
ETS1 [14-16]. As part of our studies to characterize the ETS1 
promoter, we examined the ETS1 promoter region for trans- 
location in 18 cases of malignancy associated with 11q23 
translocations. Consistent with recently published results 
demonstrating that 11q23 translocations occur at a consid- 
erable distance from the ETS1 gene [18, 19], we failed to docu- 
ment any chromosome translocations associated with 11q23. 
However, we did identify a patient whose leukemic cell DNA 
consistently showed an altered ETS1 restriction enzyme frag- 
ment pattern using multiple restriction enzymes. Analysis 
showed that these alterations were within the promoter re- 
gion of ETS1. We demonstrated that this altered restriction 
enzyme fragment resulted from a double strand break that 
mapped to the major DNaseI-hypersensitive site associated 
with the ETS1 promoter. Thus, our study demonstrates that 
altered restriction enzyme fragment migration can result from 
artifactual DNA breaks occurring at major DNaseI-hypersen- 
sitive sites in leukemic cells. In light of this, our work pro- 
vides an important cautionary tale for workers investigating 
potential sites of chromosomal translocations. 
MATERIALS AND METHODS 
Patient Material 
Bone marrow (BM) samples from patients with acute leuke- 
mia were screened for cytogenetic abnormalities as part of 
a routine diagnostic workup. Eighteen patients were selected 
based on chromosome aberrations involving 11q23 and exten- 
sive BM involvement with leukemic cells, and three patients 
with apparent deletions of chromosome 11 that included 
11q23 were selected. Table I summarizes the cytogenetic ab- 
normalities of these patients. Fourteen samples were supplied 
by the Pediatric Oncology Group, St. Louis, MO, and seven 
were from The University of Michigan Medical Center, Ann 
Arbor, Michigan. Genomic DNA was isolated, as previously 
described [20], from purified leukemic cells as well as from 
peripheral blood (PB) cells from seven normal subjects. 
Genomic Southern Blot Analysis 
Genomic DNA (5 ~tg) from BM of patients with acute leuke- 
mia or white blood cells (WBC) from normal controls was 
digested with various restriction enzymes according to con- 
ditions suggested by the manufacturer. DNA fragments were 
fractionated according to size by electrophoresis on 0.7% or 
0.9% agarose gels and were transferred to nitrocellulose. 
Membranes were baked at 80°C for 2 hours under vacuum 
and then prehybridized at 42°C in a solution containing 50% 
formamide, 5 x SSC, I x Denhardt's solution, 25 mM sodium 
phosphate (pH 6.5), and 250 ~g/ml Torula RNA for 3-4 hours. 
Hybridizations were performed for 18 to 24 hours under simi- 
lar conditions except for addition of 10% dextran sulfate and 
1 x 106 cpm/ml of the specific DNA probe (2 x 105-106 
cpm/ng probe). The DNA probe consisted of a 442 base pair 
(bp} EcoRI/XbaI fragment from the 5' end of a 1,900-bp ETS1 
cDNA [7]. This probe contained 58 bp of 5' untranslated re- 
gion and 384 bp of ETS1 coding sequence, ending at an in- 
ternal XbaI site (Fig. 1). DNA probes were labeled by nick 
translation. After hybridization, membranes were washed 
for 10 minutes at room temperature in 2 x SSC, 0.1% SSC 
and then for I hour at 55°C in 0.1x SSC, 0.1% SSC. Mem- 
branes were then air-dried briefly and exposed to XAR film 
for varying times at -70°C with intensifying screens. 
Analysis of DNaseI-Hypersensitive Sites 
Nuclei were isolated from human peripheral T cells after cell 
lysis in RSB buffer (10 mM Tris [pH 7.4], 10 mM NaC1, 5 mM 
MgC12) containing 0.5% NP-40. The nuclei were resuspended 
to a concentration of approximately 106/ml, and equal ali- 
quots were exposed to increasing concentrations of DNaseI 
for 15 minutes. DNaseI digestions were stopped by adding 
equal volumes of a solution containing 1% SDS, 600 mM 
NaC1, 20 mM Tris (pH 7.4), and 5 mM EDTA. DNA was then 
isolated and analyzed as outlined above. 
Isolation and Characterization of Genomic Clones 
Approximately 1 × 106 recombinant phage from a Sau3A 
partial digest of normal human PBL DNA cloned into ~,Fix 
(Stratagene, San Diego, CA) (a gift from Dr. J. Lowe, Univer- 
sity of Michigan, Ann Arbor, MI) were screened with the 
32p-labeled ETSl-specific DNA probe described above. Posi- 
tively hybridizing clones were purified to homogeneity by 
restriction endonuclease and partial DNA sequence analysis. 
RESULTS 
11q23 is a common breakpoint observed in acute leukemia. 
Because the protooncogene ETS1 had been localized to 11q23, 
investigators have hypothesized that ETS1 rearrangement 
plays a role in the leukemic process [12-16]. Although this 
hypothesis was tested previously by investigators who used 
DNA probes homologous to the 3' region of human ETS1 to 
examine Southern blots of normal and leukemic DNA, we 
used a novel ETS1 probe from the 5' region of the human 
cDNA to seek rearrangements in the promoter/enhancer re- 
gion of ETS1. 
Southern blot analyses were performed using DNA sam- 
ples from seven normal control subjects and 21 leukemic pa- 
tients with chromosome 11q23 aberrations. These blots were 
hybridized with the 442-bp XbaI fragment isolated from the 
5' terminus of the human ETS1 cDNA (Fig. 1). If rearrange- 
ment of the ETS1 gene occurred in these patients we would 
expect to see novel bands in the digests of leukemic DNA 
as compared with control DNA. Southern blots of control 
DNAs digested with BamHI, EcoRI, HindIII and KpnI were 
prepared. After hybridization with the 5' ETS1 specific cDNA 
fragment and autoradiography, an identical restriction pat- 
tern was observed for the seven control samples (Fig. 2) (data 
not shown). Likewise, an identical restriction pattern was 
seen among 20 of 21 leukemic samples tested (Fig. 2) (data 
not shown). A novel restriction pattern was detected upon 
analysis of one patient with a balanced translocation involv- 
ing chromosomes 11q23 and 4q21. As shown in Fig. 2, novel 
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T a b l e  1 Cl in ica l  a n d  cy togene t i c  cha rac te r i s t i c s  of p a t i en t s  w i t h  11q23 aber ra t ions  
Patient/age (yr)/sex Diagnosis Karyotype 
1/2/M ALL/null cell 
2/1/M ALL/pre-B cell 
3/0.09/F ALL/null cell 
4/0.22/M ALL/null cell 
5/8/F ALL/pre-B cell 
6/0.29/F ALL/null cell 
7/14/M ALL/null cell 
8/4/F ALL/T-cell 
9/0.84/F ALL/null cell 
10/10/F ALL/null cell 
11/5/M ALL/T-cell 
12/0.14/M ALL/null cell 
13/14/M ALL/null cell 
14/10/F ALL/null cell 
15/4/F AML/M5a 
16/65/F AML/M5a 
17/7/M ALL b 
18/12/M ALL b 
19/4/M ALL 6 
20/1/M ALL b 







82,XY, - 2, - 3, - 4,t(4;11)(q21;q23)x2, - 5, - 7, - 9, - 9, - 13, - 14, 




45,X, - Y,del(6)(q13q21),del(11)(q14) 
46,XY,t(11;19)(q23;p13.3) 
46,XY,t(4;11)(q21;q23},i(7)(q10) 








Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia. 
" Complete karyotype not available. 
b More detailed phenotype not available. 
F i g u r e  1 Structure of the ETS1 cDNA: 5' untranslated region (shaded box), ETS1 open reading frame (open box), 
and 3' untranslated region (crosshatched box}. The probe consisted of the 442-bp fragment at the 5' region of the ETS1 
cDNA (5' ETS1 cDNA) and included 58 bp of 5' untranslated region and 384 bp of ETS1 coding sequence. 
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Figure 2 Analysis of the 5' ETS1 exon restriction pattern in patients with 11q23 translocations. Southern blot analy- 
sis of 5 ~g DNA from white blood cells of three normal control (NC) subjects and bone marrow of four patients with 
acute leukemia (patients 2, 6, 13, and 14) digested with BamHI (Barn) and EcoRI (RI) (lanes 2-14) and probed with 
the 5' ETS1 cDNA fragment. Lane I contains 32p-labeled ~. DNA digested with HindIII. Of interest are the novel bands 
(16.5 and 4.7 kb, respectively) detected in the BamHI and EcoRI digests of patient 13. 
16.5 and 4.7 kb bands were noted in the BamHI and EcoRI 
digests respectively. 
To define the potential translocation detected in this pa- 
tient further, we constructed a genomic map of ETS1 and, 
from this, designed additional genomic DNA probes. The 
5' ETS1 cDNA probe was used to screen a genomic library 
prepared from human peripheral blood lymphocytes. Posi- 
tively hybridizing phage clones were isolated and mapped 
with several restriction endonucleases. Clone ).1613 yielded 
a 6.5-kb EcoRI fragment that corresponded to the 6.5-kb band 
observed on Southern blots probed with the ETS1 5' fragment. 
This 6.5-kb fragment was subcloned (ETS 1.3) and sequenced. 
It contained exon 1, as determined by homology to human 
ETS1 cDNA sequence, as well as the promoter region of ETS1 
(S. Kim and C. Thompson, manuscript in preparation). Clone 
X1609 yielded two BamHI fragments measuring 4 and 5 kb, 
respectively, and corresponding in length to two of the 
BamHI restriction fragment bands observed on Southern blots 
probed with the 5' ETS1 cDNA fragment. The two BamHI 
fragments were subcloned and partially sequenced. The 5-kb 
clone (ETS 1.1) contained the 109 bp from the 5' end of exon 
2, and the 4-kb (ETS 1.2) clone contained the remaining 
9 bp of exon 2 as well as all of exon 3 (Fig. 3). To determine 
which fragment had acquired an altered migration pattern 
in the DNA from patient (PT) 13, we used the ETS 1.3 genomic 
clone containing the ETS1 promoter/enhancer region, first 
exon, and 5' end of the first intron to isolate two ETSl-specific 
genomic DNA probes that flanked the first exon. The first 
probe (5' ETS 1.3) contained the 850-bp EcoRI-HindIII frag- 
ment from the 5' end of ETS 1.3. The second probe (3' ETS 
1.3) contained the 500-bp XbaI-EcoRI fragment from the 3' 
end of ETS 1.3 (Fig. 3). 
Southern blots containing restriction enzyme-digested 
DNA from PT 13 leukemia cells were consecutively hybrid- 
ized with the 5' and 3' ETS 1.3 probes. In BamHI-restricted 
DNA, the 3' ETS 1.3 probe detected both the germline 22 kb 
fragment and the novel 16.5 kb fragment detected with the 
original 5' ETS1 cDNA probe (Fig. 4), whereas the 5' ETS 1.3 
fragment detected both the germline 22-kb fragment and a 
novel band of 5.6 kb (Fig. 5). In EcoRI-restricted DNA, the 
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Figure 3 Genomic organization of 5' end of ETS1. Shown are restriction maps of the genomic ETS1 clones used 
in these analyses as determined by restriction and partial sequence analysis. Location of exons 1-3 (bars), promoter 
region (box). Also shown in a schematic of the 5' ETS1 cDNA probe. The two genomic probes, 5" and 3" ETS 1.3, are 
diagrammed (top). 
3' ETS 1.3 probe detected the germline 6.5-kb fragment and 
novel 4.7-kb fragment detected with the original 5' ETS1 cDNA 
probe, whereas the 5' ETS 1.3 fragment detected both the 
germline 6.5-kb fragment and a 1.8-kb fragment. As shown 
in Fig. 5, the novel BamHI and EcoRI sites detected in this 
single patient were localized to the same site in the genomic 
map of ETS1 and, in both cases, the size of the novel bands 
detected by probes 5' and 3' of the breakpoint equaled the 
size of the parental fragment detected in control DNA by both 
probes. Likewise, data obtained using two additional restric- 
tion enzymes localized a DNA break to this same site (SacI 
and KpnI, data not shown). Thus, all four enzymes confirmed 
we were detecting a DNA break rather than a translocation. 
To determine whether the break was an isolated artifact of 
DNA preparation, we obtained a second sample of leukemic 
cells from this patient and reanalyzed it by Southern blot. 
The results were identical to those detected initially, imply- 
ing that the DNA break could be reproducibly observed in 
serial leukemic samples. 
We then performed DNaseI-hypersensitive site analysis 
of the ETS1 promoter region, and noted that a major site of 
nuclease sensitivity mapped to the position of the breakpoint 
detected in the DNA isolated from the leukemic cells of pa- 
tient 13 (Fig. 6), suggesting that the DNA break occurred ar- 
tifactually in preparation of DNA from the frozen leukemic 
cells and demonstrating that rearrangements in or around 
the ETSl promoter are not involved in 11q23 translocations. 
In one patient, however, we detected a DNA break which we 
mapped to the major DNaseI-hypersensitive site present in 
the ETS1 promoter. 
D I S C U S S I O N  
The association between chromosome aberrations and pro- 
tooncogenes have yielded important insights into the etiol- 
ogy of several human hematopoietic malignancies, includ- 
ing B-cell neoplasms and chronic myelogenous leukemia. 
Because the protooncogene ETS1 has been localized near the 
leukemia-specific breakpoint 11q23, that ETS1 was hypothe- 
sized to play a role in the leukemic process. Indeed, several 
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F igure  4 The aberrant restriction fragment observed in DNA from patient 13 contains the regions encoding the 
first exon. Southern blot shown in Fig. 2 was reprobed with the 3' ETS 1.3 genomic fragment. The same novel 16.5- 
and 4.7-kb bands were detected by the 5' ETS1 cDNA probe. 
cases of al tered ETS1 restr ic t ion enzyme fragments were 
repor ted in cases of 11q23 t ranslocat ion [12, 13]. As part  of 
our analysis of ETS1 gene expression, we had an opportuni ty  
to examine the ETS1 promoter  region for rearrangement  in 
18 patients wi th  11q23 translocations. None of these patients 
had  any evidence of t ranslocat ion associated wi th  the ETS1 
gene. Therefore,  our  data are consistent  wi th  recent ly  pub- 
l i shed  reports that local ize the 11q23 breakpoin t  at least sev- 
eral hundred  kilobases centromeric of the ETS1 gene [18, 19]. 
In the course of our  study, however, using mul t ip le  re- 
str ict ion enzymes,  we ident i f ied a pat ient  whose leukemic 
cell DNA consistently showed an altered ETS1 restriction en- 
zyme fragment. These observations resul ted from a break- 
poin t  that m a p p e d  in the promoter  region of ETS1. Such a 
DNA break must  be art ifactual because  a chromosome wi th  
a double-s t rand break  wi l l  undergo  loss of the centromere- 
distal  fragment during a subsequent  cell  division.  DNaseI- 
hypersensi t ive  site analysis  showed that  the break m a p p e d  
to the major nuclease-sensi t ive  site in the promoter  region 
of ETS1. Therefore, apparen t  al teration in the size of the re- 
s tr ict ion enzyme fragment alone is not sufficient justifica- 
t ion to conc lude  that  a chromosome translocat ion has oc- 
cur red  in the v ic in i ty  of a probe. Even if nonleukemic  t issue 
from the pat ient  fails to show a s imilar  fragment, an endoge- 
nous nuclease acting at DNaseI-hypersensitive sites can create 
art ifactual alterations in  restr ict ion fragment lengths in  tu- 
mor  samples.  In this light,  this  work provides an important  
caut ionary  tale for workers investigating potential  sites of 
chromosome translocation.  Previous data report ing break- 
points  involving ETS1 may have resulted from DNA breaks 
at nuclease-hypersensi t ive sites. 
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